Show simple item record

dc.contributor.authorNeoptolemos, J
dc.contributor.authorMoore, M
dc.contributor.authorCox, T
dc.contributor.authorValle, Juan W
dc.contributor.authorPalmer, D
dc.contributor.authorMcDonald, A
dc.contributor.authorCarter, R
dc.contributor.authorTebbutt, N
dc.contributor.authorDervenis, C
dc.contributor.authorSmith, D
dc.contributor.authorGlimelius, B
dc.contributor.authorCharnley, R
dc.contributor.authorLacaine, F
dc.contributor.authorScarfe, A
dc.contributor.authorMiddleton, M
dc.contributor.authorAnthoney, A
dc.contributor.authorGhaneh, P
dc.contributor.authorHalloran, C
dc.contributor.authorLerch, M
dc.contributor.authorOláh, A
dc.contributor.authorRawcliffe, C
dc.contributor.authorVerbeke, C
dc.contributor.authorCampbell, F
dc.contributor.authorBüchler, M
dc.date.accessioned2012-10-12T12:09:44Z
dc.date.available2012-10-12T12:09:44Z
dc.date.issued2012-07-11
dc.identifier.citationEffect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. 2012, 308 (2):147-56 JAMAen_GB
dc.identifier.issn1538-3598
dc.identifier.pmid22782416
dc.identifier.doi10.1001/jama.2012.7352
dc.identifier.urihttp://hdl.handle.net/10541/248616
dc.description.abstractPatients with periampullary adenocarcinomas undergo the same resectional surgery as that of patients with pancreatic ductal adenocarcinoma. Although adjuvant chemotherapy has been shown to have a survival benefit for pancreatic cancer, there have been no randomized trials for periampullary adenocarcinomas.
dc.language.isoenen
dc.rightsArchived with thanks to JAMA : the journal of the American Medical Associationen_GB
dc.subject.meshAdenocarcinoma
dc.subject.meshAged
dc.subject.meshAmpulla of Vater
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshCommon Bile Duct Neoplasms
dc.subject.meshDeoxycytidine
dc.subject.meshFemale
dc.subject.meshFluorouracil
dc.subject.meshHumans
dc.subject.meshLeucovorin
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPrognosis
dc.subject.meshSurvival Analysis
dc.subject.meshWatchful Waiting
dc.titleEffect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.en
dc.typeArticleen
dc.contributor.departmentInstitute of Translational Medicine, Liverpool Cancer Trials Unit, Liverpool Cancer Research United Kingdom Centre, University of Liverpool, Liverpool, England, United Kingdom. j.p.neoptolemos@liverpool.ac.uken_GB
dc.identifier.journalJAMAen_GB
html.description.abstractPatients with periampullary adenocarcinomas undergo the same resectional surgery as that of patients with pancreatic ductal adenocarcinoma. Although adjuvant chemotherapy has been shown to have a survival benefit for pancreatic cancer, there have been no randomized trials for periampullary adenocarcinomas.


This item appears in the following Collection(s)

Show simple item record